About Illumi Medical
Illumi Medical is a company based in Nagoya (Japan) founded in 2023. Illumi Medical has raised $5.69 million across 3 funding rounds from investors including Ogaki Kyoritsu Bank, UntroD and UntroD. Illumi Medical operates in a competitive market with competitors including PhotoPharmics, CranioVation, Adgero Biopharma, Lumeda and SpectraCure, among others.
- Headquarter Nagoya, Japan
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$5.69 M (USD)
in 3 rounds
-
Latest Funding Round
$3.44 M (USD), Series A
Apr 30, 2026
-
Investors
Ogaki Kyoritsu Bank
& 12 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Illumi Medical
Illumi Medical has successfully raised a total of $5.69M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $3.44 million completed in April 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Illumi Medical
Illumi Medical has secured backing from 13 investors, including institutional and venture fund investors. Prominent investors backing the company include Ogaki Kyoritsu Bank, UntroD and UntroD.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made in beauty, wellness, food, and sports tech.
|
Locked | Locked | Locked | |
|
Investments in deep tech and untrodden areas for societal impact.
|
Locked | Locked | Locked | |
|
A seed fund focused on regional startup investments in Japan.
|
Locked | Locked | Locked |
Investor details for Illumi Medical
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Illumi Medical
Investment portfolio details for Illumi Medical
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Illumi Medical
Detailed financials for Illumi Medical
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Illumi Medical Comparisons
Peer comparison for Illumi Medical
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Illumi Medical
Illumi Medical operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PhotoPharmics, CranioVation, Adgero Biopharma, Lumeda and SpectraCure, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Non-invasive phototherapy for Parkinson's disease is developed.
|
|
| Locked | Locked | Locked |
Minimally invasive devices for brain tumor treatment are provided.
|
|
| Locked | Locked | Locked |
Photodynamic therapy for cutaneous metastatic breast cancer is developed.
|
|
| Locked | Locked | Locked |
Photodynamic therapy device for lung cancer treatment is developed.
|
|
| Locked | Locked | Locked |
Developer of Interstitial photo dynamic therapy for solid tumours
|
Detailed competitors of Illumi Medical
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Illumi Medical
Complete news archive for Illumi Medical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Illumi Medical
Illumi Medical was founded in 2023 and raised its 1st funding round 1 year after it was founded.
Illumi Medical is headquartered in Nagoya, Japan. It is registered at Nagoya, Aichi, Japan.
Illumi Medical is a funded company, having raised a total of $5.69M across 3 funding rounds to date.
Illumi Medical was founded in 2023 in Nagoya, Japan, within the medical technology sector focused on oncology. An intravascular light irradiation system known as ET-BLIT is being developed to deliver targeted light to tissues affected by cancers including lung, pancreatic, and brain tumors. Operations center on advancing photodynamic therapy solutions for various cancer types, with research and development conducted in Japan.
Illumi Medical's top competitors include PhotoPharmics, ImPact Biotech and Adgero Biopharma.
Illumi Medical has 13 investors. Key investors include Ogaki Kyoritsu Bank, UntroD, UntroD, MTG Ventures, and Mintco.